| Literature DB >> 31869686 |
Kira Patterson1, Kaari L Linask1, Jeanette Beers1, Jizhong Zou1.
Abstract
Human induced pluripotent stem cells (iPSCs) that express stable and robust fluorescent proteins have proven to be indispensable in basic and translational research. These reporter iPSC lines can greatly facilitate cell imaging, sorting, and tracking in vitro and in vivo studies. Here, we document two reporter human iPSC lines generated by gene-editing technologies that precisely integrated one-copy of a tdTomato transgene driven by strong CAG promoter into the AAVS1 human safe harbor locus. Published by Elsevier B.V.Entities:
Year: 2019 PMID: 31869686 PMCID: PMC7046126 DOI: 10.1016/j.scr.2019.101673
Source DB: PubMed Journal: Stem Cell Res ISSN: 1873-5061 Impact factor: 2.020
Summary of lines.
| iPSC line names | Abbreviation in figures | Gender | Age | Ethnicity | Genotype of locus | Disease |
|---|---|---|---|---|---|---|
| NHLBIi003-A-1 | ND2-tdTom1 | Male | Newborn | Unknown | CAG-tdTomato | N/A |
| NHLBIi003-A-2 | ND2-tdTom4 | Male | Newborn | Unknown | CAG-tdTomato | N/A |
Fig. 1.(A) Images of phase contrast and flurorescence microscopy showing the expression of tdTomato and pluripotency markers by ND2-tdTom1 and ND2-tdTom4 iPSCs. (B) Flow cytometry analysis of pluripotency markers of ND2-tdTom1 and ND2-tdTom4 iPSCs. (C) Teratoma formation assay shows ND2-tdTom1 and ND2-tdTom4 iPSCs can generate three germ layers in vivo.
Reagents details. RRID Requirement for antibodies: use http://antibodyregistry.org/ to retrieve RRID for antibodies and include ID in table as shown in examples.
| Antibodies used for immunocytochemistry/flow-cytometry | |||
|---|---|---|---|
| Antibody | Dilution | Company Cat # and RRID | |
| Pluripotency Markers | Mouse anti-SOX2 | 1:250 | BioLegend, Cat# 656102, RRID: AB_2,562246 |
| Pluripotency Markers | Rabbit anti-NANOG | 1:400 | Cell Signaling Technology, Cat# 4903, RRID: AB_10559205 |
| Pluripotency Markers | Rabbit anti-OCT4 | 1:400 | Thermo Fisher, Cat# 701756, RRID: AB_2633031 |
| Pluripotency Markers | Mouse anti-SSEA4 | 1:1000 | Cell Signaling Technology, Cat# 4755, RRID: AB_1264259 |
| Secondary Antibodies | Donkey anti-Mouse IgG (Alexa Fluor 488) | 1:400 | Thermo Fischer, Cat# A21202, RRID: AB_141607 |
| Secondary Antibodies | Donkey anti-Rabbit IgG (Alexa Fluor 594) | 1:400 | Thermo Fischer, Cat# A21207, RRID: AB_141637 |
| Flow Cytometry Antibodies | Anti-Tra-1-60-DyLight 488 | 1:50 | Thermo Fischer, Cat# MA1–023-D488X, RRID: AB_2536700 |
| Flow Cytometry Antibodies | Anti-Nanog-Alexa Fluor 488 | 1:50 | Millipore, Cat# FCABS352A4, RRID: AB_10807973 |
| Flow Cytometry Antibodies | Anti-SSEA-4-Alexa Fluor 488 | 1:50 | Thermo Fischer, Cat# 53-8843-41, RRID: AB_10597752 |
| Flow Cytometry Antibodies | Mouse-IgM-DyLight 488 | 1:50 | Thermo Fischer, Cat# MA1-194-D488, RRID: AB_2536969 |
| Flow Cytometry Antibodies | Rabbit IgG-Alexa Fluor 488 | 1:50 | Cell Signaling Technology, Cat# 4340S, RRID: AB_10694568 |
| Flow Cytometry Antibodies | Mouse IgG3-FITC | 1:50 | Thermo Fischer, Cat# 11-4742-42, RRID: AB_2043894 |
|
| |||
| Target | Forward/Reverse primer (5′ – 3′) | ||
| Mycoplasma detection primers (qPCR) | GPO-1_MGSO/724bp | 5′-ACGGCCCAGACTCCTACGGGAGGCAGCAGTA | |
| 5′-CCATGCACCATCTGTCACTCTGTTAACCTC | |||
| House-keeping gene primers (qPCR) | GAPDH-3/488 bp | 5′-GGGAGCCAAAAGGGTCATCA | |
| 5′-TGATGGCATGGACTGTGGTC | |||
Characterization and validation.
| Classification | Test | Result | Data |
|---|---|---|---|
| Morphology | Photography | Normal |
|
| Phenotype | Qualitative analysis: Immunocytochemistry | Positive for SOX2, OCT4, NANOG, SSEA-4 |
|
| Quantitative analysis: Flow Cytometry (tdTom1, tdTom4) | TRA-1-60 (98.21%, 95.77%); NANOG (99.30%, 92.39%); SSEA-4 (93.11%, 99.46%); tdTomato (99.66%, 99.89%) |
| |
| Genotype | Karyotype (G-banding) and resolution | 46XY; Resolution 425–500 |
|
| Identity | Microsatellite PCR (mPCR) OR STR analysis | Not performed | N/A |
| 15 loci plus amelogenin (Promega PowerPlex 16) tested, all matched | Available with the authors | ||
| Mutation analysis (IF APPLICABLE) | Sequencing | N/A | N/A |
| Southern Blot | Monoallelic targeted integration without random integration |
| |
| Microbiology and virology | Mycoplasma testing by qPCR | Negative |
|
| Differentiation potential | Teratoma formation | Teratoma formed with three germ layers: Ectoderm, Mesoderm, and Endoderm |
|
| Donor screening (OPTIONAL) | HIV 1 + 2 Hepatitis B, Hepatitis C | N/A | N/A |
| Genotype additional info (OPTIONAL) | Blood group genotyping | N/A | N/A |
| HLA tissue typing | N/A | N/A |
Resource Table:
| Unique stem cell lines identifier | NHLBIi003-A-1 |
| NHLBIi003-A-2 | |
| Alternative names of stem cell lines | ND2-tdTom1 (NHLBIi003-A-1) |
| ND2-tdTom4 (NHLBIi003-A-2) | |
| Institution | National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health, Bethesda, USA |
| Contact information of distributor | Dr. Jizhong Zou |
| Type of cell lines | iPSC |
| Origin | Human |
| Cell Source | Fibroblast |
| Clonality | Clonal |
| Method of reprogramming | Episomal vectors |
| Multiline rationale | Stable and bright fluorescent protein reporter iPSC lines generated from a previously published wild-type iPSC line |
| Gene modification | Yes |
| Type of modification | Transgene expression (fluorescent reporter and drug-resistance genes) by targeted integration |
| Associated disease | N.A. |
| Gene/locus | AAVS1/PPP1R12C |
| Method of modification | CRISPR/Cas9 |
| Name of transgene or resistance | tdTomato and Puromycin |
| Inducible/constitutive system | Constitutive |
| Date archived/stock date | September 2019 |
| Cell line repository/bank |
|
| Ethical approval | The original fibroblast CCD-1079sk (ATCC® CRL-2097) was obtained from ATCC ( |